PhorMed, Inc., a clinical stage biopharmaceutical company founded in 2019, is developing a drug internally called RLC/929 or 12-O-tetradecanoylphorbol-13-acetate (TPA) aka phorbol-12-myristate-13-acetate (PMA).
PhorMed focuses on the development of human therapeutics that function at the cellular level, a cell repair therapy that targets along multiple cell lines, and fortunately these targets are important for the pathogenesis of several diseases, allowing it to become a Platform Technology. Our area of study covers Oncology/Hematology, Neurology and Anti-Inflammatory.
The company’s goal is to become first-line treatments for the disease states we are studying and potentially be a new drug class for Anti-Inflammation and Neurology.
Molecule
Active Platforms
A Myriad of Lateral Platforms
What is RLC/929?
RLC/929 is PhorMed’s groundbreaking therapeutic compound, developed to address life-threatening diseases in oncology, neurology, and inflammatory conditions. It represents a new class of precision medicine, designed to treat complex diseases with high efficacy while minimizing side effects.
RLC/929 Molecule
Croton Tiglium L.
Five indications are presently in the pipeline and the company will continue to expand through it’s continued dedication in research and development We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for our patients and society.
A Versatile, Targeted Approach
- Oncology: Treating Acute Myeloid Leukemia (AML) and Hodgkin’s Lymphoma by targeting and disrupting the growth pathways of cancer cells.
- Neurology: Crossing the blood-brain barrier to address neurodegenerative diseases like Parkinson’s, protecting and repairing brain cells.
- Inflammation: Modulating the body’s inflammatory response in Acute Respiratory Distress Syndrome (ARDS), reducing damage caused by cytokine storms.